about
T Cells and Cancer: How Metabolism Shapes ImmunityTryptophan Catabolism in Chronic Viral Infections: Handling Uninvited GuestsDisturbed Amino Acid Metabolism in HIV: Association with Neuropsychiatric SymptomsTrial Watch: Immunomodulatory monoclonal antibodies for oncological indicationsTrial Watch: Immunogenic cell death inducers for anticancer chemotherapyTargeting immune checkpoints in malignant gliomaThe Kynurenine Pathway Is a Double-Edged Sword in Immune-Privileged Sites and in Cancer: Implications for ImmunotherapyEngineering New Approaches to Cancer VaccinesStructural Study of a Flexible Active Site Loop in Human Indoleamine 2,3-Dioxygenase and Its Functional Implications.Trial Watch: Peptide-based anticancer vaccines.Classification of current anticancer immunotherapiesTrial watch: Naked and vectored DNA-based anticancer vaccinesThe kynurenine to tryptophan ratio as a prognostic tool for glioblastoma patients enrolling in immunotherapy.The Emerging Hallmarks of Cancer MetabolismHost genetic predictors of the kynurenine pathway of tryptophan catabolism among treated HIV-infected Ugandans.Trial Watch-Small molecules targeting the immunological tumor microenvironment for cancer therapy.Trial Watch: Immunotherapy plus radiation therapy for oncological indications.Hepatitis C virus drives the pathogenesis of hepatocellular carcinoma: from immune evasion to carcinogenesis.Distinct Patterns of Tryptophan Maintenance in Tissues during Kynurenine Pathway Activation in Simian Immunodeficiency Virus-Infected Macaques.Tryptophan-2,3-Dioxygenase (TDO) deficiency is associated with subclinical neuroprotection in a mouse model of multiple sclerosis.Impact of Metabolism on T-Cell Differentiation and Function and Cross Talk with Tumor Microenvironment.Binding properties of different categories of IDO1 inhibitors: a microscale thermophoresis study.Assessment of Tryptophan Uptake and Kinetics Using 1-(2-18F-Fluoroethyl)-l-Tryptophan and α-11C-Methyl-l-Tryptophan PET Imaging in Mice Implanted with Patient-Derived Brain Tumor Xenografts.Therapy-induced microenvironmental changes in cancer.The AhR is involved in the regulation of LoVo cell proliferation through cell cycle-associated proteins.Programming the immune checkpoint to treat hematologic malignancies.Major developments in the design of inhibitors along the kynurenine pathway.The immune microenvironment of HPV-negative oral squamous cell carcinoma from never-smokers and never-drinkers patients suggests higher clinical benefit of IDO1 and PD1/PD-L1 blockade.Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Developing immunotherapeutic strategies to target brain tumors.Suppression of indoleamine-2,3-dioxygenase 1 expression by promoter hypermethylation in ER-positive breast cancer.Adaptive immunity programmes in breast cancer.The effect of cyclophosphamide on the immune system: implications for clinical cancer therapy.Chimeric antigen receptors for treatment of glioblastoma: a practical review of challenges and ways to overcome them.The stress kinase GCN2 does not mediate suppression of antitumor T cell responses by tryptophan catabolism in experimental melanomas.Indoleamine 2,3-dioxygenase activity is associated with regulatory T cell response in acute Puumala hantavirus infection.Targeting amino acid metabolism for cancer therapy.Unleashing the immune response against childhood solid cancers.Metabolic Cooperation and Competition in the Tumor Microenvironment: Implications for Therapy.The interplay between metabolic remodeling and immune regulation in glioblastoma.
P2860
Q26766427-CC5EF672-9177-4C84-8057-1BEC78F7A789Q26797214-B78610DE-AF2F-4C84-BB0B-BFF1B7076768Q26800052-2E86B259-048C-4B03-846B-94929A67002CQ26996518-8E1FEAC0-39B5-409F-9538-63BE1324B378Q27004011-9AF3725B-C27F-4297-AEAD-C085B30F1D1DQ28072012-2CDED9C6-514A-41B5-9693-30F1AA4F8717Q28073631-EBB2BE90-BD25-4539-819E-DB2EDCEF82CEQ28085563-1148FB5E-E706-4DFD-B81D-B05794391AC7Q33742950-6C19EB7F-31CC-40AB-808E-32B9AE274835Q34483345-F7C2F4A0-7B30-44C3-801B-0E49E6811927Q35149637-9CE12264-3603-47F5-916F-5B9C188F68DFQ35798986-172FD83C-8DFF-49B0-959A-AA7A86DF76FAQ35994427-A9B00A1E-3570-4615-9E0B-C054B4B41AA1Q36468964-AD1098C9-3227-4C7A-B355-32A6FAC4C1F5Q37047893-A20217F2-BFE8-41A0-8055-FA260842F7C2Q37079141-BD08B41B-787A-4DAA-92B2-3B40DF625DA6Q37308207-CE0A09FA-5886-4D12-90B8-ACD2A57F71B9Q37399410-81CA00FF-45F0-48E9-83BB-242DB39B9155Q37513129-91FC421C-4823-4CBE-BDEB-76B862EBCCD8Q37602166-B953AF8D-058F-43DF-967A-D7F3E389B437Q37694431-C9F7C043-A917-43F2-B47E-6941B8B96558Q38647699-E00FBC36-18F3-4ECB-BDAD-0C35E7FF1131Q38739230-2E0B83BF-6AEB-4F4D-8A19-FE7F9659DB43Q38756772-9D50DD3E-43A8-404C-82A5-C2AB3425B86CQ38795308-DBB2DB74-4A40-4989-B5A8-D18BD6190100Q38806070-F33AE8E2-109F-4558-AD5E-62524646443BQ38808400-BFC37B93-E50A-4B29-8B3A-0924E79DF39DQ38811007-5A110733-5EC3-456D-9894-99FD6BA3733FQ38832886-FD1B005C-1960-47E0-AE26-AB1A79F8679CQ38851464-141612AC-42E7-44F1-974C-D285EF6918E5Q38875015-5F2BF291-8D02-4471-883B-5CB5C456611CQ38937896-F00CCD78-1DF9-4C31-B393-2B9ABE7CE91CQ38959130-FD97F958-791F-4DB6-B806-884309B1314CQ38987239-C2B71AE9-55A1-4B9E-BD8A-BA797539CA02Q38998436-76D50BA4-98CC-4915-8CD6-0C1F0F4E79C9Q39037291-0C8303CC-7D4A-4F82-B35E-344E007A529FQ39042260-966A6A64-F277-4CB4-9D35-BCE05882C47AQ39224315-6B79955C-B598-42CE-80D3-481FFFD5037AQ39265746-D58AE292-A6CC-4E6F-AD0B-C956F8770890Q39328710-8A7EB64B-2AAF-4F1C-B4CF-54E9BB6E0468
P2860
description
2014 nî lūn-bûn
@nan
2014 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Trial watch: IDO inhibitors in cancer therapy
@ast
Trial watch: IDO inhibitors in cancer therapy
@en
Trial watch: IDO inhibitors in cancer therapy
@nl
type
label
Trial watch: IDO inhibitors in cancer therapy
@ast
Trial watch: IDO inhibitors in cancer therapy
@en
Trial watch: IDO inhibitors in cancer therapy
@nl
prefLabel
Trial watch: IDO inhibitors in cancer therapy
@ast
Trial watch: IDO inhibitors in cancer therapy
@en
Trial watch: IDO inhibitors in cancer therapy
@nl
P2860
P50
P3181
P1433
P1476
Trial watch: IDO inhibitors in cancer therapy
@en
P2093
Eugene P Kennedy
P2860
P304
P3181
P356
10.4161/21624011.2014.957994
P50
P577
2014-11-01T00:00:00Z